在耐火性异常性炎症性肌肉病症中使用Telitacicept补充疗法:来自试点研究的见解
Huajie Gao1, Jing Lin1, Mengge Yang1
1Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rheumatology (Oxford, England)
|November 4, 2024
概括
泰利塔西塞普在成年人中有效治疗异常性炎症性肌肉病 (IIM),显著降低了普雷尼松剂量并改善了肌肉力量. 这表明telitacicept是对IIM管理的有希望的治疗方法.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异形性炎症性肌肉病变 (IIM) 包含一组罕见的自身免疫性疾病,其特征是慢性肌肉炎症.
- 目前对IIM的治疗方法通常涉及广泛的免疫抑制,导致严重的副作用,并且在耐药病例中有效性有限.
研究的目的:
- 为了评估telitacicept的治疗疗效作为一种附加疗法在患有异常发炎性肌肉病 (IIM) 的成年患者.
- 评估telitacicept对IIM患者临床表现,疾病活性和肌肉功能的影响.
主要方法:
- 一项前性研究包括11名成年IIM患者,他们接受了至少3个月的telelitacicept (160 mg/周) 治疗.
- 临床反应使用ACR/EULAR标准进行评估. 监测疾病活动,肌肉炎损伤和肌肉性能 (MMT-8). 还测量了肌酸激酶水平.
主要成果:
- 所有11名患者都达到了ACR/EULAR改善标准.
- 预尼松剂量 (27.05至12.05毫克) 和肌酸酶水平 (2670.27至561.09单位/升) 显著降低.
- 手动肌肉测试8 (MMT-8) 的得分显著改善,从109.18提高到137.64.
结论:
- 泰利塔西在治疗耐火性异常性炎症性肌肉病症方面表现出显著的疗效.
- 添加telitacicept导致皮质类固醇需求大幅下降.
- 泰利塔西塞普特 (Telitacicept) 是治疗IIM的一种有前途的治疗方案.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Tumor Immunotherapy
484
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
484
Inflammatory Bowel Disease IV: Pharmacological Management
116
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
116
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143


